AI-generated · cited to primary sources · not investment advice
Gland Pharma (543245) Feb 2026 Filing Analysis
Does management do what it says?
The company confirmed that three products remain in line for approval following the successful launch of six others in the complex pipeline. (5 met across 5 tracked commitments)
“I'm pleased to inform you that our partner has received approval for liraglutide in the U.S., and we are ready for the U.S. launch in this quarter.”
See the full cited Management analysis of Gland Pharma
How durable is the business?
The US market remains the dominant revenue driver, contributing 52% of group revenue, with growth supported by nine new molecule launches this quarter. (3 expanding)
“Group Revenue Contribution 8,685 vs 7,293 19% YoY; US Contribution to the Group 9M FY26 52%”
See the full cited Business Model analysis of Gland Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.